Westfield Capital Management Co. LP Sells 2,120 Shares of Merck & Co., Inc. (NYSE:MRK)

Westfield Capital Management Co. LP reduced its stake in Merck & Co., Inc. (NYSE:MRK) by 2.1% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 98,514 shares of the company’s stock after selling 2,120 shares during the period. Westfield Capital Management Co. LP’s holdings in Merck & Co., Inc. were worth $8,260,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Resources Investment Advisors Inc. increased its holdings in Merck & Co., Inc. by 41.4% in the 4th quarter. Resources Investment Advisors Inc. now owns 11,717 shares of the company’s stock valued at $895,000 after buying an additional 3,430 shares during the period. Nomura Asset Management Co. Ltd. boosted its stake in shares of Merck & Co., Inc. by 20.4% in the 4th quarter. Nomura Asset Management Co. Ltd. now owns 1,837,508 shares of the company’s stock valued at $140,403,000 after purchasing an additional 311,732 shares in the last quarter. Bessemer Group Inc. boosted its stake in shares of Merck & Co., Inc. by 973.1% in the 4th quarter. Bessemer Group Inc. now owns 770,416 shares of the company’s stock valued at $58,866,000 after purchasing an additional 698,622 shares in the last quarter. NS Partners Ltd acquired a new stake in shares of Merck & Co., Inc. in the 4th quarter valued at approximately $206,000. Finally, Pitcairn Co. boosted its stake in shares of Merck & Co., Inc. by 97.7% in the 4th quarter. Pitcairn Co. now owns 42,450 shares of the company’s stock valued at $3,243,000 after purchasing an additional 20,974 shares in the last quarter. Institutional investors own 75.36% of the company’s stock.

Several equities research analysts recently commented on MRK shares. Svb Leerink started coverage on shares of Merck & Co., Inc. in a research report on Friday, August 16th. They set an “outperform” rating and a $103.00 target price on the stock. JPMorgan Chase & Co. lifted their target price on shares of Merck & Co., Inc. from $90.00 to $93.00 and gave the stock an “overweight” rating in a research report on Friday, June 14th. Citigroup lifted their target price on shares of Merck & Co., Inc. from $84.00 to $95.00 and gave the stock a “buy” rating in a research report on Friday, June 21st. They noted that the move was a valuation call. ValuEngine downgraded shares of Merck & Co., Inc. from a “buy” rating to a “hold” rating in a research report on Thursday, August 1st. Finally, Morgan Stanley lifted their target price on shares of Merck & Co., Inc. from $84.00 to $90.00 and gave the stock an “overweight” rating in a research report on Friday, June 21st. Three equities research analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the stock. The stock has a consensus rating of “Buy” and an average target price of $93.29.



In other news, CFO Robert M. Davis sold 216,718 shares of the stock in a transaction dated Tuesday, June 25th. The stock was sold at an average price of $85.43, for a total value of $18,514,218.74. Following the transaction, the chief financial officer now directly owns 354,378 shares of the company’s stock, valued at $30,274,512.54. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Richard R. Deluca sold 6,427 shares of the stock in a transaction dated Friday, August 9th. The shares were sold at an average price of $85.09, for a total value of $546,873.43. Following the completion of the transaction, the executive vice president now directly owns 103,223 shares in the company, valued at $8,783,245.07. The disclosure for this sale can be found here. Corporate insiders own 0.27% of the company’s stock.

Shares of NYSE MRK traded up $0.39 during trading on Thursday, hitting $83.31. The stock had a trading volume of 7,982,772 shares, compared to its average volume of 10,525,021. Merck & Co., Inc. has a 12 month low of $66.10 and a 12 month high of $87.35. The company has a debt-to-equity ratio of 0.82, a current ratio of 1.21 and a quick ratio of 0.92. The company has a market capitalization of $213.71 billion, a PE ratio of 19.20, a PEG ratio of 1.70 and a beta of 0.53. The firm has a fifty day moving average of $84.76 and a two-hundred day moving average of $81.88.

Merck & Co., Inc. (NYSE:MRK) last posted its earnings results on Tuesday, July 30th. The company reported $1.30 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.16 by $0.14. Merck & Co., Inc. had a net margin of 21.10% and a return on equity of 43.34%. The firm had revenue of $11.76 billion during the quarter, compared to analyst estimates of $10.94 billion. During the same quarter in the prior year, the business posted $1.06 EPS. The business’s revenue was up 12.4% compared to the same quarter last year. On average, equities analysts expect that Merck & Co., Inc. will post 4.91 earnings per share for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Monday, October 7th. Investors of record on Monday, September 16th will be given a dividend of $0.55 per share. This represents a $2.20 annualized dividend and a yield of 2.64%. The ex-dividend date of this dividend is Friday, September 13th. Merck & Co., Inc.’s dividend payout ratio is currently 50.69%.

Merck & Co., Inc. Profile

Merck & Co, Inc provides healthcare solutions worldwide. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, chronic hepatitis C virus, HIV-1 infection, intra-abdominal, fungal infection, insomnia, and inflammatory diseases.

See Also: Risk Tolerance

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.